Bach Fiona L, Sairally B Zeyah F, Latthe Pallavi
Birmingham Women's Hospital, Mindelsohn Way, Birmingham, B15 2TG, UK.
The University of Birmingham, Edgbaston Birmingham, B15 2TT, UK.
Int Urogynecol J. 2020 Jul;31(7):1289-1297. doi: 10.1007/s00192-020-04252-1. Epub 2020 Mar 4.
Faecal incontinence (FI) is prevalent in postmenopausal women. Oestrogen receptors have been identified in the anal sphincter and have been implicated in the pathogenesis and potential treatment. We sought to evaluate the literature regarding the impact of local and systemic oestrogen therapy on FI in postmenopausal women.
A systematic review of all studies in postmenopausal women was performed to establish how oestrogen therapy affects FI. Eight articles were deemed eligible for inclusion following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Their quality was assessed using the Cochrane risk-of-bias tool (RoB-2) and Newcastle-Ottawa quality assessment scale.
One randomised controlled trial (RCT), two cohort studies, one observational and four cross-sectional studies were identified. The RCT showed an improvement in FI with anal oestrogen (p = 0.002), but this improvement was also observed in the placebo arm (p = 0.013) and no difference was seen between these groups. A prospective observational study demonstrated significant improvement with an oestrogen patch (p = 0.004), but had no control group. Conversely, a large prospective cohort study demonstrated an increased hazard ratio of FI with current (1.32; 95% CI, 1.20-1.45) and previous oestrogen use (1.26; 95% CI, 1.18-1.34) compared with non-users.
All studies had a high risk of bias and had conflicting views on the effects of oestrogen on FI in postmenopausal women. This review has identified the need for further research in this area by highlighting the paucity of good research for evidence-based practice. We believe that a further RCT of local oestrogen is mandated to draw a valid conclusion.
粪失禁(FI)在绝经后女性中很常见。已在肛门括约肌中鉴定出雌激素受体,其与发病机制及潜在治疗有关。我们试图评估有关局部和全身雌激素治疗对绝经后女性粪失禁影响的文献。
对所有绝经后女性的研究进行系统综述,以确定雌激素治疗如何影响粪失禁。按照系统评价和Meta分析的首选报告项目(PRISMA)指南,八篇文章被认为符合纳入标准。使用Cochrane偏倚风险工具(RoB-2)和纽卡斯尔-渥太华质量评估量表对其质量进行评估。
确定了一项随机对照试验(RCT),两项队列研究,一项观察性研究和四项横断面研究。该RCT显示肛门使用雌激素后粪失禁有所改善(p = 0.002),但在安慰剂组中也观察到这种改善(p = 0.013),且两组之间无差异。一项前瞻性观察性研究表明,使用雌激素贴片后有显著改善(p = 0.004),但没有对照组。相反,一项大型前瞻性队列研究表明,与未使用者相比,目前使用(1.32;95% CI,1.20 - 1.45)和既往使用雌激素(1.26;95% CI,1.18 - 1.34)的女性发生粪失禁的风险比增加。
所有研究都有较高的偏倚风险,并且对于雌激素对绝经后女性粪失禁的影响存在相互矛盾的观点。本综述通过强调基于循证实践的高质量研究的匮乏,确定了该领域需要进一步研究。我们认为有必要进行另一项局部雌激素的RCT以得出有效的结论。